Abbott Laboratories (NYSE:ABT) Releases FY 2026 Earnings Guidance

Abbott Laboratories (NYSE:ABT) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 5.550-5.800 for the period, compared to the consensus EPS estimate of 5.670. The company issued revenue guidance of -. Abbott Laboratories also updated its Q1 2026 guidance to 1.120-1.180 EPS.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock opened at $120.82 on Thursday. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a 12-month low of $113.50 and a 12-month high of $141.23. The company’s fifty day simple moving average is $125.65 and its two-hundred day simple moving average is $128.68. The firm has a market cap of $210.10 billion, a PE ratio of 15.14, a price-to-earnings-growth ratio of 2.01 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The company had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter last year, the business posted $1.34 EPS. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio (DPR) is presently 31.58%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ABT. Sanford C. Bernstein raised their price objective on shares of Abbott Laboratories from $150.00 to $154.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Barclays raised their price target on shares of Abbott Laboratories from $162.00 to $169.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. Evercore ISI increased their target price on Abbott Laboratories from $142.00 to $144.00 and gave the company an “outperform” rating in a research note on Monday, January 5th. Wells Fargo & Company boosted their price target on Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a research note on Thursday, October 16th. Finally, The Goldman Sachs Group reduced their price objective on Abbott Laboratories from $157.00 to $152.00 and set a “buy” rating for the company in a report on Friday, January 9th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $147.42.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Management issued 2026 guidance calling for 6.5%–7.5% organic sales growth and adjusted diluted EPS of $5.55–$5.80 (≈10% growth at the midpoint), which signals confidence in recovery and future earnings growth. Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook
• Positive Sentiment: Abbott received CE mark in Europe for the TactiFlex Duo ablation catheter, expanding its AFib device portfolio and supporting medtech growth in Europe. Abbott receives CE Mark for the TactiFlex Duo Ablation Catheter
• Positive Sentiment: Coverage pieces highlight Abbott’s steady dividend history and durable businesses (medical devices and diagnostics), supporting its appeal to income-focused investors. Want Decades of Passive Income? 2 Stocks to Buy.
• Neutral Sentiment: Q4 adjusted EPS of $1.50 matched analyst consensus (GAAP EPS $1.01); full-year 2025 adjusted EPS was $5.15 — earnings met expectations but offered limited upside surprise. Abbott Laboratories Trading Down 0.3%
• Neutral Sentiment: Analysts and previews were active around Q4 results, with some firms revising models ahead of the release — implies increased scrutiny but no consensus catalyst. Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q4 Earnings
• Negative Sentiment: Revenue missed estimates due to weakness in the diagnostics segment — ongoing volatility from lower COVID-19 testing demand and a reported freeze on foreign aid weighed on top-line results. This is the main near-term driver of selling pressure. Abbott misses quarterly revenue estimates on weakness in diagnostics segment

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ABT. Centaurus Financial Inc. boosted its position in shares of Abbott Laboratories by 2.8% during the third quarter. Centaurus Financial Inc. now owns 3,964 shares of the healthcare product maker’s stock worth $531,000 after acquiring an additional 109 shares during the last quarter. OmniStar Financial Group Inc. purchased a new position in Abbott Laboratories during the third quarter worth $1,173,000. Keystone Financial Group raised its stake in shares of Abbott Laboratories by 11.3% in the third quarter. Keystone Financial Group now owns 41,285 shares of the healthcare product maker’s stock valued at $5,401,000 after acquiring an additional 4,204 shares during the period. FSA Wealth Management LLC boosted its stake in shares of Abbott Laboratories by 12.9% during the 3rd quarter. FSA Wealth Management LLC now owns 885 shares of the healthcare product maker’s stock worth $119,000 after purchasing an additional 101 shares during the period. Finally, Morningstar Investment Management LLC bought a new stake in Abbott Laboratories in the third quarter worth about $5,842,000. Institutional investors own 75.18% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.